Development

Articles

MedPharm has received a multi-million dollar investment by Ampersand Capital Partners to diversify its service offering and regional coverage.

MedPharm Receives Investment from Ampersand Capital Partners

David W. Osborne, PhD, is Chief Scientific Officer and Founder, Independent Derm Solutions, LLC, 4215 Creekside Court, Fort Collins, CO 80525.

Yug Varma, PhD, is CEO at Phi Therapeutics

Jason Carbol is manager of Chemistry, Manufacturing, and Controls at Dow Development Laboratories (DDL), a division of Symbio, jcarbol@dowdevelopmentlabs.com.

Case studies compare efficacy testing of preservatives for topical formulations with probiotic actives.

Formulating Topical Products Containing Live Microorganisms as the Active Ingredient

Guy Bouvier, guybouvier06FR@gmail.com, is nonclinical coordination and evaluation manager at Nestle Skin Health. 

Jean-Guy Boiteau is head of process research and development at Nestle Skin Health. 

Amandine Gras is product development coordinator and CMC expert at Nestle Skin Health. 

Anne-Pascale Luzy is head of in vitro toxicology at Nestle Skin Health.

Jean-Pierre Etchegaray is pharmaceutical development expert at Nestle Skin Health.

The authors offer recommendations for permissible daily exposures and concentration limits of elemental impurities for dermal drug products.

Determination of Dermal PDE for Pharmaceutical Products

The authors of the study believe it could have significant implications for the discovery of new dermatological products for major diseases such as psoriasis.

New Study Challenges Current Theories on Skin Delivery of Macromolecules

Jennifer Markarian is manufacturing reporter for Pharmaceutical Technology.

Characterization of the product and process is key for process development and scale-up of topical drug manufacturing using a QbD approach.

Using QbD in Topical Drug Manufacturing

Sienna Biopharmaceuticals has filed for an IPO, expecting to raise over $74 million

Topical Drug Developer Plans IPO

This article will clarify reasonable expectations for the responsibilities of topical product formulation developers and for excipient suppliers regarding the information and samples for experiments needed for QbD.

Impact of Quality by Design on Topical Product Excipient Suppliers, Part II: Reasonable Expectations

This article will equip the excipient vendor with an understanding of QbD from the perspective of the topical pharmaceutical product manufacturer.

Impact of Quality by Design on Topical Product Excipient Suppliers, Part I: A Drug Manufacturer's Perspective

Tapemark, a full-service CDMO specializing in transdermal, oral thin film, and topical drug-delivery technologies, is exhibiting at CPhI.

Tapemark Showcases Transdermal, Oral Thin Film, and Topical Drug-Delivery Systems at CPhI

Agnes Shanley is senior editor of Pharmaceutical Technology.

Analytics and science-based approaches are shedding more light on these complex dosage forms, promising to improve process control and product design.

Formulation and Drug Delivery, Topical Drugs